Abbott announced today, at the American College of Rheumatology Annual Scientific Meeting in Chicago, the results of their Phase-3 ABILITY-1 trial for the study of HUMIRA. The drug is used to treat patients who suffer from the disease active non-radiographic axial spondyloarthritis (axSpA) in addition to related conditions.
HUMIRA proved its efficacy with more than twice as many HUMIRA patients than those receiving placebo showing improvement by the 12th week of the...
↧